MDXH

MDxHealth S.A. (MDXH) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Growth Durability

Revenue base remains small at $1.6 per share, limiting scale advantages.

Gross margin is solid at 57.7%, but operating margin is still negative at -16.6%.

No recent news indicates a catalyst for sustained top-line acceleration.

Profitability

Net margin remains deeply negative at -32.2%, showing the business is still unprofitable.

Return on invested capital is negative at -12.7%, indicating value destruction on capital deployed.

Return on equity is distortedly high at 4.0x due to negative equity, so it is not a reliable sign of profitability.

Financial Health

Current ratio is only 1.08, leaving limited liquidity cushion.

Cash ratio of 0.59 suggests the company is not highly cash-rich relative to short-term obligations.

Leverage metrics remain strained, with debt-to-assets at 64.3% and negative equity-related ratios.

Valuation

EV/Sales of 1.26 is not demanding on a revenue basis, but it is offset by weak profitability.

Negative earnings and cash flow make P/E and FCF-based valuation metrics unreliable.

The market appears to be pricing in a turnaround rather than current fundamentals.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MDxHealth S.A.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →